Please login to the form below

Not currently logged in
Email:
Password:

Dr Keith Bragman joins Alacrita

He becomes a partner at the firm’s London office

Alacrita Dr Keith BragmanLife sciences consultancy Alacrita has appointed Dr Keith Bragman as a partner in its London office.

Dr Bragman brings a wealth of industry experience to the firm, having served on the Science and Technology Select Committee at the House of Commons, worked with the Bill and Melinda Gates Foundation and at the UK government's department for international development.

He has held a number of senior leadership positions at pharmaceutical companies, including serving as head of global development and research for UCB's Japanese business, vice president and senior partner for biotechnology at Quintiles, and European head of clinical oncology at Bristol-Myers Squibb.

Managing partner Anthony Walker said: “We are delighted to welcome Keith to our product development practice as we build a best-in-class consulting practice to help companies develop better therapeutics.

“Keith is an experienced executive with deep and broad knowledge of the drug development process and a sound understanding of the challenges faced by senior management.

“He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”

30th June 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...